相关实验视频

Updated: Jun 12, 2025

Electrolytic Inferior Vena Cava Model EIM of Venous Thrombosis

Electrolytic Inferior Vena Cava Model EIM of Venous Thrombosis

Published on: July 12, 2011

血小板整合素αIIbβ3在静脉血栓形成小鼠模型中发挥着关键作用

Brian D Adair^1,2,3, Conroy O Field⁴, José L Alonso^1,2

¹Division of Nephrology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.

Nature communications

|October 4, 2024

概括

一种修改后的铁洛非班,m-铁洛非班,通过向血小板αIIbβ3,有效地防止静脉血栓形成,而不会增加出血风险. 这表明,对于高风险患者来说,有潜在的新疗法.

科学领域:

血管生物学血管生物学
血液学血液学血液学
药理学药理学是指药理学的学科.

背景情况:

静脉血栓症 (VT) 是一种普遍的血管疾病,具有显著的死亡率和复发率.
血小板激活和中性粒细胞积累是静脉瘤开始的关键.
血小板糖蛋白αIIbβ3在静脉瘤中的作用尚不清楚,目前的抑制剂会增加出血风险.

研究的目的:

为了研究血小板αIIbβ3在静脉血栓形成中的作用.
为了评估改性铁洛菲班 (m-铁洛菲班) 作为潜在的血栓预防剂的疗效和安全性.

主要方法:

使用冷-EM和新位表达试验,描述m-tirofiban与αIIbβ3的相互作用.
评估m-tirofiban对血小板聚合和凝块收缩的作用.
在小鼠模型中评估m-tirofiban在抑制静脉血栓形成方面的疗效,并进行出血评估.

主要成果:

证实M-tirofiban不会激活αIIbβ3,结构和功能数据支持这一点.
M-tirofiban抑制了激素诱导的血小板聚合,但保留了凝块收缩.
在体内,m-tirofiban在未加剧出血的情况下抑制了小鼠的静脉血栓形成.

结论:

血小板αIIbβ3在静脉血栓形成过程中起着至关重要的作用.
M-tirofiban在静脉瘤预防中显示出有前途的治疗特征,可以在不影响血液静止的情况下减轻血栓形成.
结构定义的αIIbβ3抑制剂,如m-tirofiban,需要对风险较高的静脉瘤和出血患者进行进一步的研究.

更多相关视频

Stenosis of the Inferior Vena Cava: A Murine Model of Deep Vein Thrombosis

Stenosis of the Inferior Vena Cava: A Murine Model of Deep Vein Thrombosis

Published on: December 22, 2017

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models

Published on: January 5, 2024

相关概念视频

Intracellular Signaling Affects Focal Adhesions

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...

Venous Thrombosis I: Introduction

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...

Formation of the Platelet Plug

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...